Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Sep 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of the HPV vaccine in women who have been treated for cervical dysplasia, a condition where abnormal cells develop on the cervix due to the human papillomavirus (HPV). Researchers want to find out if getting the HPV vaccine after treatment can help lower the chances of these abnormal cells coming back. The study is currently looking for women aged 18 and older who have received treatment for HPV-related issues but have not previously been vaccinated against HPV.

If you decide to participate in this trial, you will receive the HPV vaccine and be monitored to see how it affects your health and any recurrence of cervical dysplasia. Participating in this study can help improve understanding of how the HPV vaccine can be used as a preventive measure after treatment. It’s a great opportunity to contribute to important research that may benefit many women in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Treatment of HPV-related disease
• Exclusion Criteria:
• • Previous HPV vaccination